A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients
Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present,...
Gespeichert in:
Veröffentlicht in: | OncoTargets and therapy 2021-01, Vol.14, p.1783-1790 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1790 |
---|---|
container_issue | |
container_start_page | 1783 |
container_title | OncoTargets and therapy |
container_volume | 14 |
creator | Gu, Jiahui Wang, Wantong Wang, Shizhuo |
description | Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined.
From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment.
All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews.
The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control. |
doi_str_mv | 10.2147/OTT.S300523 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7955772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669417962</galeid><sourcerecordid>A669417962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</originalsourceid><addsrcrecordid>eNptkcFrHCEUh6W0NMm2p96L0EtL2a0zOupcCsuwaQuhWZrNWRx9JoaZcaIzC_nva8g2bKB4eKLf-_nkQ-hDQVZlwcS3y91udUUJqUr6Cp0WhZBLXlPy-mh_gs5SuiOEc1myt-iEUlEKWcpTpNf4D0wxpBHM5PeAG50AX02zfcDB4YLi6wmiHwBvc9nrZOZOR7wZ_XQLnQ_e4ga6Dv-GMHY69fjzdtOEXn_BWz15GKb0Dr1xukvw_lAX6Pp8s2t-Li8uf_xq1hdLwxidlgwsKw0zjAjjqopxZ6EVklmmGWfWcWkpsS3TrWtJy0VJ65I4SWpdE8kMpQv0_Sl3nNserMlvR92pMfpexwcVtFcvbwZ_q27CXom6qkTOW6BPh4AY7mdIk7oLcxzyzKqsSCGlIOSIutEdKD-4kMNM75NRa85rVoiaP1Kr_1B5Wei9CQM4n89fNHx9ajDZRYrgngcviHrUrLJmddCc6Y_Hf31m_3mlfwGH2qGL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501887002</pqid></control><display><type>article</type><title>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</title><source>Taylor & Francis Open Access</source><source>Dove Press Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Gu, Jiahui ; Wang, Wantong ; Wang, Shizhuo</creator><creatorcontrib>Gu, Jiahui ; Wang, Wantong ; Wang, Shizhuo</creatorcontrib><description>Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined.
From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment.
All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews.
The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S300523</identifier><identifier>PMID: 33727828</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Analysis ; Cancer ; Care and treatment ; Case Series ; Case studies ; Cervix ; Chemotherapy ; Diagnosis ; Disease control ; Fibroids ; Gynecology ; Health aspects ; Hysterectomy ; Immunohistochemistry ; Lymphatic system ; Medical research ; Medicine, Experimental ; Mesenchyme ; Morphology ; Pathology ; Patients ; Prognosis ; Risk groups ; Stem cells ; Surgery ; Tumors ; Uterus ; Vagina</subject><ispartof>OncoTargets and therapy, 2021-01, Vol.14, p.1783-1790</ispartof><rights>2021 Gu et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Gu et al. 2021 Gu et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</citedby><cites>FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955772/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955772/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3849,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33727828$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Jiahui</creatorcontrib><creatorcontrib>Wang, Wantong</creatorcontrib><creatorcontrib>Wang, Shizhuo</creatorcontrib><title>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined.
From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment.
All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews.
The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control.</description><subject>Analysis</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Case Series</subject><subject>Case studies</subject><subject>Cervix</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease control</subject><subject>Fibroids</subject><subject>Gynecology</subject><subject>Health aspects</subject><subject>Hysterectomy</subject><subject>Immunohistochemistry</subject><subject>Lymphatic system</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mesenchyme</subject><subject>Morphology</subject><subject>Pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Risk groups</subject><subject>Stem cells</subject><subject>Surgery</subject><subject>Tumors</subject><subject>Uterus</subject><subject>Vagina</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkcFrHCEUh6W0NMm2p96L0EtL2a0zOupcCsuwaQuhWZrNWRx9JoaZcaIzC_nva8g2bKB4eKLf-_nkQ-hDQVZlwcS3y91udUUJqUr6Cp0WhZBLXlPy-mh_gs5SuiOEc1myt-iEUlEKWcpTpNf4D0wxpBHM5PeAG50AX02zfcDB4YLi6wmiHwBvc9nrZOZOR7wZ_XQLnQ_e4ga6Dv-GMHY69fjzdtOEXn_BWz15GKb0Dr1xukvw_lAX6Pp8s2t-Li8uf_xq1hdLwxidlgwsKw0zjAjjqopxZ6EVklmmGWfWcWkpsS3TrWtJy0VJ65I4SWpdE8kMpQv0_Sl3nNserMlvR92pMfpexwcVtFcvbwZ_q27CXom6qkTOW6BPh4AY7mdIk7oLcxzyzKqsSCGlIOSIutEdKD-4kMNM75NRa85rVoiaP1Kr_1B5Wei9CQM4n89fNHx9ajDZRYrgngcviHrUrLJmddCc6Y_Hf31m_3mlfwGH2qGL</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Gu, Jiahui</creator><creator>Wang, Wantong</creator><creator>Wang, Shizhuo</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</title><author>Gu, Jiahui ; Wang, Wantong ; Wang, Shizhuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-4ed42c4c407cf5546fdeb784d4a464df68d30db4abfb0b6723920f809a9084c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Case Series</topic><topic>Case studies</topic><topic>Cervix</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease control</topic><topic>Fibroids</topic><topic>Gynecology</topic><topic>Health aspects</topic><topic>Hysterectomy</topic><topic>Immunohistochemistry</topic><topic>Lymphatic system</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mesenchyme</topic><topic>Morphology</topic><topic>Pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Risk groups</topic><topic>Stem cells</topic><topic>Surgery</topic><topic>Tumors</topic><topic>Uterus</topic><topic>Vagina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Jiahui</creatorcontrib><creatorcontrib>Wang, Wantong</creatorcontrib><creatorcontrib>Wang, Shizhuo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Jiahui</au><au>Wang, Wantong</au><au>Wang, Shizhuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>1783</spage><epage>1790</epage><pages>1783-1790</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal tumors that originate from perivascular epithelioid cells. The uterus is the second most common organ to be affected by PEComa. Most PEComas are benign and the prognosis is usually good. Surgery is the main treatment at present, and adjuvant therapy is mainly used for malignant cases. However, because of the lack of described cases, the best diagnosis and treatment of these tumors cannot be determined.
From 2009 to 2020, 13 patients from Shengjing Hospital (China Medical University), with uterine PEComa, who met the inclusion criteria and appropriate pathological diagnosis were enrolled in this study. Clinical, pathological, and therapeutic features were retrospectively analyzed to determine the best approach towards diagnosis and treatment.
All the enrolled patients underwent surgical treatment; four of them had a malignant PEComa. Three of the malignant patients received chemotherapy after surgery; among them, one died, another showed no obvious recurrence after regular re-examination, and the third did not undergo any further treatment despite short-term recurrence. However, upon regular re-examination, no progress was observed. The fourth malignant patient did not receive chemotherapy after surgery and showed no obvious recurrence during regular reviews.
The preoperative diagnosis of uterine PEComa lacks specificity and therefore is often confused with uterine leiomyoma or leiomyosarcoma. We conclude that uterine PEComa can be diagnosed by combined analysis of immunohistochemistry and post-operative pathology. Though surgical resection is still the main treatment, high-risk patients can be given adjuvant treatment to strengthen disease control.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>33727828</pmid><doi>10.2147/OTT.S300523</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1178-6930 |
ispartof | OncoTargets and therapy, 2021-01, Vol.14, p.1783-1790 |
issn | 1178-6930 1178-6930 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7955772 |
source | Taylor & Francis Open Access; Dove Press Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
subjects | Analysis Cancer Care and treatment Case Series Case studies Cervix Chemotherapy Diagnosis Disease control Fibroids Gynecology Health aspects Hysterectomy Immunohistochemistry Lymphatic system Medical research Medicine, Experimental Mesenchyme Morphology Pathology Patients Prognosis Risk groups Stem cells Surgery Tumors Uterus Vagina |
title | A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T08%3A11%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Retrospective%20Case%20Study%20of%2013%20Uterine%20Perivascular%20Epithelioid%20Cell%20Neoplasm%20(PEComa)%20Patients&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Gu,%20Jiahui&rft.date=2021-01-01&rft.volume=14&rft.spage=1783&rft.epage=1790&rft.pages=1783-1790&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S300523&rft_dat=%3Cgale_pubme%3EA669417962%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501887002&rft_id=info:pmid/33727828&rft_galeid=A669417962&rfr_iscdi=true |